Opendata, web and dolomites

GI-BCT SIGNED

Disruptive imaging technology for accurate and painless breast cancer diagnosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GI-BCT project word cloud

Explore the words cloud of the GI-BCT project. It provides you a very rough idea of what is the project "GI-BCT" about.

provides    machinery    later    painful    granted    recalls    tissue    combines    precise    healthcare    save    cancer    images    die    estimate    mammography    performing    compression    imaging    natural    saving    640    formed    amount    centers    first    revenue    2d    programs    environment    poor    treatment    lowering    dense    computed    sold    yielding    therapeutic    stage    survival    breasts    avoiding    interferometry    95    procedure    service    solid    56    routing    entering    missed    gi    5m    start    detection    commercialization    team    investment    scientific    profits    disease    prevalent    patents    market    clinical    potentially    produces    85b    3d    gratxray    breast    59    resolution    21    bct    worked    hired    portfolio    demonstrated    grating    68    women    q1    countries    rate    400    positives    patient    contracts    sales    mortality    employees    agents    painless    discrimination    tomography    beur    2021    roi    industry    scanned    patients    15    false    unnecessary    form    outcomes    efficient    trials    207    disruptive    net    discovered    size    meur    screening    patent    reduce    ready    limited    contrast   

Project "GI-BCT" data sheet

The following table provides information about the project.

Coordinator
GRATXRAY AG 

Organization address
address: PARK INNOVAARE
city: VILLIGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gratxray.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRATXRAY AG CH (VILLIGEN) coordinator 50˙000.00

Map

 Project objective

Breast cancer is the most prevalent form of cancer in women, as 1 in 9 women are affected and 1 in 30 will die from the disease. Early detection is essential to reduce the mortality, thus countries have established routing screening programs. The problem is that main screening procedure of mammography is painful for patients, produces high rate of false positives for women with dense breast tissue, provides limited contrast, low-resolution and poor tissue discrimination properties. False positives lead to performing unnecessary therapeutic procedures. Also cancer in dense breasts is missed out by mammography, lowering survival outcomes when discovered in later stage. GratXray is entering the 3,56 BEUR size breast imaging market with our disruptive grating interferometry-based breast computed tomography – GI-BCT technology. GI-BCT will provide painless, efficient and precise breast cancer imaging. The breast will be scanned in its natural state in 3D, without compression and contrast agents, yielding images with a much higher contrast and better resolution. Thus saving €1,85B in healthcare costs in Europe and US by avoiding recalls, €640 000 from machinery costs for breast centers and potentially save treatment costs in the amount of €95 000 per patient. We have worked for the past 15 years in GI-BCT research and have a solid patent portfolio of 8 granted patents. Currently, we have demonstrated our technology in operational environment, and we are ready to start first clinical trials in 2D with the goal to make first sales in Q1 2021. We have formed a team that combines strong scientific, industry and user know-how. We estimate that a further investment of €5M and 3 years is required to reach the commercialization stage. We estimate that in year 6 we have hired 50 employees, sold 59 systems per year, have 207 service contracts, revenue of 68 MEUR, net profits of 21 MEUR and reach ROI of 4 (400%).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GI-BCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GI-BCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

TankSensor (2020)

Smart monitoring solution for better procurement and supply chain management - Speeding up chemical industry digitalization

Read More  

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More